Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Sarepta Therapeutics Inc (SRPT), VIVUS, Inc. (VVUS): The Week’s Biotech Winner and Loser

Page 1 of 2

What’s the best way to choose the biotech winner and loser of the past week?

The easiest route would involve the companies with the biggest share price movements. That would make Idenix Pharmaceuticals Inc (NASDAQ:IDIX) the obvious loser with its over 30% drop after the FDA requested additional preclinical safety information for a hepatitis C drug. But that movement came from volatility that arose despite the fact that this wasn’t the first time Idenix Pharmaceuticals Inc (NASDAQ:IDIX) has faced a similar delay.

But there were two companies last week that moved over 4% on the days of their news. And the stories of Sarepta Therapeutics Inc (NASDAQ:SRPT) and VIVUS, Inc. (NASDAQ:VVUS) displayed the overall industry pattern much better.

Winner: Sarepta

Sarepta Therapeutics Inc

Sarepta Therapeutics Inc (NASDAQ:SRPT) shares have soared over 800% in the past year thanks solely to the Duchenne muscular dystrophy drug eteplirsen. DMD is a degenerative X-linked muscle disease that usually leaves the young male patients wheelchair-bound. The life expectancy is under 30.

Eteplirsen’s new data comes from a phase 2b extension study that was testing the drug against placebo using the six-minute walk, an important DMD metric. Trial patients would walk for six minutes and have the distance measured over the course of 84 weeks. Boys taking eteplirsen showed an improvement of 46.4 meters over the placebo arm. The boys also showed a relatively stable overall decline in walking distance.

Sarepta Therapeutics Inc (NASDAQ:SRPT) is overly dependent on eteplirsen’s success. But the efficacy data continues to impress and the safety profile hasn’t thrown up any warning signs. An FDA approval would serve a disease that currently has no real treatment options, and cement Sarepta Therapeutics Inc (NASDAQ:SRPT)’s developer reputation at the same time.

Loser: Vivus

VIVUS, Inc. (NASDAQ:VVUS) was a news darling last year before the launch of its obesity drug Qysmia, which limped slowly out of the gate. But the company also has the erectile dysfunction drug Stendra.

VIVUS, Inc. (NASDAQ:VVUS) reported results from a placebo-controlled study indicating that Stendra is effective within 15 minutes. The results were meant to inspire a label addition to the product, which was previously approved with a 30 minute dosage note.

Fifteen minutes is an improvement on the hour recommended for Pfizer Inc. (NYSE:PFE)’s Viagra, but there are already once-daily ED drugs available that don’t require pre-game prep time. And there’s also the pesky fact that Stendra still hasn’t launched, despite receiving FDA approval last spring and a CHMP recommendation earlier this year. That’s because VIVUS, Inc. (NASDAQ:VVUS) is hoping for a big pharma partner to  help push Stendra out into a saturated market.

But the delay could cost Stendra a shot at even a slice of that market. ED drugs will soon begin dropping off the patent cliff like lemmings. Viagra went off-patent in Europe last week, though it has a few more years of protection in the United States. ED drugs are notoriously costly and branded drugs won’t stand up against a wave of cheaper generics.

Foolish final thoughts

Sarepta Therapeutics Inc (NASDAQ:SRPT)’s share price skyrocket over the past year isn’t sustainable. But eteplirsen continues to show fantastic data in an area of unmet need, which could lead to an approval and higher pricing to counteract the low patient population.

Page 1 of 2

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!